Royce & Associates LP lessened its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 17.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 287,207 shares of the medical instruments supplier's stock after selling 59,938 shares during the period. Royce & Associates LP owned about 5.29% of Mesa Laboratories worth $37,874,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC boosted its holdings in Mesa Laboratories by 34.1% during the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier's stock worth $51,000 after buying an additional 100 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Mesa Laboratories in the third quarter worth about $70,000. Amundi boosted its stake in shares of Mesa Laboratories by 81.6% during the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier's stock worth $91,000 after acquiring an additional 297 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Mesa Laboratories by 6.5% during the 3rd quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier's stock worth $206,000 after acquiring an additional 97 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in shares of Mesa Laboratories during the 3rd quarter valued at about $207,000. Institutional investors and hedge funds own 90.60% of the company's stock.
Mesa Laboratories Price Performance
NASDAQ MLAB traded down $0.74 during trading hours on Thursday, reaching $123.50. The company's stock had a trading volume of 35,139 shares, compared to its average volume of 36,848. The firm has a market capitalization of $671.10 million, a price-to-earnings ratio of -2.67 and a beta of 0.82. The company's 50-day moving average is $138.46 and its two-hundred day moving average is $129.19. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. Mesa Laboratories, Inc. has a 1-year low of $83.68 and a 1-year high of $155.12.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. On average, equities analysts predict that Mesa Laboratories, Inc. will post 8 EPS for the current year.
Mesa Laboratories Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, February 28th were given a $0.16 dividend. The ex-dividend date was Friday, February 28th. This represents a $0.64 annualized dividend and a dividend yield of 0.52%. Mesa Laboratories's dividend payout ratio (DPR) is -1.38%.
Mesa Laboratories Company Profile
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Featured Articles
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
